Logo - Ocular Services On Demand

Publication Reference Index

The majority of our work involves studies that support the development of new ocular therapies and devices.  We have also participated in investigative studies that have advanced the field of preclinical development.  You may also filter for Development phase, (e.g., Safety) ophthalmology discipline (e.g., ocular imaging) and therapeutic class (e.g., Gene and Cell therapies).

Filter Results by...

Publication Title Investigation Type Development Phase Therapy Class Discipline(s)
Lucentis
Safety Evaluation of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 3 Months 		Approved Therapy Safety Fab Protein
  • Ophthalmic Exam
  • Electrodiagnostics
  • Ocular Imaging
 Detail

Lucentis
Safety Evaluation of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 3 Months

Invest Ophthalmol Vis Sci, 41 (4):S142 (2000).

Publication Authors
O’Neill, C. A, Christian B. J., Murphy, C. J., Miller, P., Verhoeve, J., Leedle, R., Dubeilzig, R. R., Beyer, J. C., Albert, D. M., and Davis, M
Full Publication
Lucentis
Safety Evaluation of Differing Schedules of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 2 Months 		Approved Therapy Safety Fab Protein
  • Ophthalmic Exam
  • Electrodiagnostics
  • Ocular Imaging
 Detail

Lucentis
Safety Evaluation of Differing Schedules of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 2 Months

Toxicologist, 60 (1):97 (2001).

Publication Authors
O’Neill, C. A, Miller, P., Christian B. J., Leatherberry, G., Miller, J., Leedle, R., Dubeilzig, R. R., Albert, D. M., Beyer, J. C., Nork, T. M., Wabers, H., Neider, M., and Murphy, C. J.
Full Publication
Lucentis
Characterization of a Monkey Model of Laser-Induced Choroidal Neovascularization (CNV) 		Approved Therapy Safety Fab Protein
  • Ocular Imaging
 Detail

Lucentis
Characterization of a Monkey Model of Laser-Induced Choroidal Neovascularization (CNV)

The Toxicologist, 72 (S-1): 311, (2003)

Publication Authors
Christian, B. J., Nork, T. M, Leedle, R. A., Miller, J. M., and O'Neill, C. A.
Full Publication
Lucentis
26-Week Intravitreal Injection Toxicity Study with rhuFab VEGF in Cynomolgus Monkeys with an 8-Week Recovery 		Approved Therapy Safety Fab Protein
  • Ophthalmic Exam
  • Electrodiagnostics
  • Ocular Imaging
 Detail

Lucentis
26-Week Intravitreal Injection Toxicity Study with rhuFab VEGF in Cynomolgus Monkeys with an 8-Week Recovery

 Association for Research in Vision and Ophthalmology Annual Meeting. Invest Ophthalmol Vis Sci., 44 – electronic abstract (2003).

Publication Authors
O'Neill, C. A., Miller, P. E., Christian, B. J., Beyer, J. C., Bentley, E., Abrams, G. A., Verhoeve, J. N., Nork, T. M., Leedle, R. A., Dubielzig, R. R., Albert, D. M., and Murphy, C. J.
Full Publication
Lucentis
Prevention of Laser Photocoagulation Induced Choroidal Neovascularization Lesions by Intravitreal Doses of Ranibizumab in Cynomolgus Monkeys 		Approved Therapy Pharmacology Fab Protein
  • Ocular Imaging
 Detail

Lucentis
Prevention of Laser Photocoagulation Induced Choroidal Neovascularization Lesions by Intravitreal Doses of Ranibizumab in Cynomolgus Monkeys

Invest Ophthalmol Vis Sci,  – electronic abstract (2009)

Publication Authors
Z. Yao A, D.A. West B, P. Kuebler A, A. Bricarello , J.M. Miller , V. Bantseev, P.E. Miller, T. M.Nork, L. Damico B.
Full Publication